Prognostic Gleason grade grouping: data based on the modified Gleason scoring system


References 1 Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998–2006 2 Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154–64 3 Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897–903 4 Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 2008; 5: 24–34 5 Beebe-Dimmer JL, Cetin K, Shahinian V et al. Timing of androgen deprivation therapy and fracture among elderly men with prostate cancer in the United States. Pharmacoepidemiol Drug Saf 2012; 21: 70–8 6 Lu-Yao G, Shao Y-H, Moore D, Shih W, Lin Y, Jang T. Fracture following androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int 2013; 111: 745–52 7 Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen deprivation therapy for prostate cancer? Eur Urol 2012 (Epub ahead of print) 8 Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol 2009; 56: 609–16

Cite this paper

@inproceedings{BeebeDimmer2013PrognosticGG, title={Prognostic Gleason grade grouping: data based on the modified Gleason scoring system}, author={Jennifer L. Beebe-Dimmer and Stephen J. Freedland}, year={2013} }